Feng Tian

Dr. Feng Tian got his Bachelor's Degree in Tsinghua University, School of Life Sciences and his Ph.D. from Harvard Molecular and Cellular Biology (Stem Cell and Regenerative Biology) program. During his postdoctoral work at Boston Children's Hospital, he has been awarded by NIH K99/R00 Pathway to Independence Grant (Project Number: EY032181). His main achievements include mechanistic investigations of neural degeneration and regeneration in human diseases such as amyotrophic lateral sclerosis (ALS) and glaucoma, which have been reflected in a number of peer-reviewed high-profile journals. By combining multiple genetic tools (such as CRISPR tools and AAV vectors) and bioinformatic methods (including machine learning algorithms for drug candidate identification), Dr. Tian’s long-term research goal is to (1) molecularly and computationally dissect the epigenomic programs determining cell death/survival in neurodegenerative diseases and brain tumors; and (2) develop novel therapeutics that protect and regenerate the nervous system in disease conditions.

​

Dr. Tian has been invited as the reviewer for several journals in the field, including but not limited to Neural Regeneration Research, Experimental Neurology, Journal of Tissue Engineering and Regenerative Medicine. As part of the effort to promote the diversity, equity, and inclusion of the research community and young generations, Dr. Tian has contributed to STEM fair at Boston public schools, Massachusetts, and International levels. He has also been serving at the Early Career Reviewer (ECR) Program of NIH.